Piper Jaffray Companies Lowers Becton Dickinson and (BDX) Price Target to $250.00

Becton Dickinson and (NYSE:BDX) had its target price decreased by analysts at Piper Jaffray Companies to $250.00 in a research report issued on Tuesday, The Fly reports. The brokerage presently has an “overweight” rating on the medical instruments supplier’s stock. Piper Jaffray Companies’ target price would suggest a potential upside of 5.55% from the stock’s current price. Piper Jaffray Companies also issued estimates for Becton Dickinson and’s Q1 2019 earnings at $2.79 EPS, Q2 2019 earnings at $2.90 EPS, Q3 2019 earnings at $3.07 EPS, Q4 2019 earnings at $3.33 EPS, FY2019 earnings at $12.10 EPS, Q1 2020 earnings at $3.17 EPS, Q2 2020 earnings at $3.42 EPS, Q3 2020 earnings at $3.67 EPS, Q4 2020 earnings at $3.68 EPS and FY2020 earnings at $13.94 EPS.

Several other brokerages also recently commented on BDX. Morgan Stanley lifted their target price on Becton Dickinson and from $250.00 to $280.00 and gave the stock an “equal weight” rating in a report on Thursday, October 4th. KeyCorp reaffirmed a “buy” rating and set a $264.00 target price on shares of Becton Dickinson and in a report on Friday, August 3rd. Citigroup lifted their target price on Becton Dickinson and from $274.00 to $283.00 and gave the stock a “buy” rating in a report on Wednesday, August 8th. Barclays initiated coverage on Becton Dickinson and in a report on Monday, October 15th. They set an “equal weight” rating and a $278.00 target price on the stock. Finally, Royal Bank of Canada reaffirmed a “hold” rating and set a $248.00 target price on shares of Becton Dickinson and in a report on Friday, August 3rd. Five investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $254.71.

NYSE BDX opened at $236.86 on Tuesday. The company has a debt-to-equity ratio of 0.95, a quick ratio of 0.81 and a current ratio of 1.23. Becton Dickinson and has a twelve month low of $209.91 and a twelve month high of $265.87. The firm has a market cap of $64.40 billion, a P/E ratio of 21.51, a PEG ratio of 1.44 and a beta of 1.19.

Becton Dickinson and (NYSE:BDX) last released its quarterly earnings data on Tuesday, November 6th. The medical instruments supplier reported $2.93 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $2.93. Becton Dickinson and had a return on equity of 13.84% and a net margin of 1.47%. The company had revenue of $4.40 billion for the quarter, compared to the consensus estimate of $4.36 billion. During the same quarter last year, the business posted $2.40 EPS. Becton Dickinson and’s revenue for the quarter was up 39.0% on a year-over-year basis. On average, analysts forecast that Becton Dickinson and will post 12.56 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Ascension Asset Management LLC lifted its stake in shares of Becton Dickinson and by 4.2% in the 2nd quarter. Ascension Asset Management LLC now owns 4,970 shares of the medical instruments supplier’s stock valued at $1,191,000 after purchasing an additional 200 shares during the period. Bfsg LLC lifted its stake in shares of Becton Dickinson and by 1.9% in the 2nd quarter. Bfsg LLC now owns 10,515 shares of the medical instruments supplier’s stock valued at $2,519,000 after purchasing an additional 201 shares during the period. Toth Financial Advisory Corp lifted its stake in shares of Becton Dickinson and by 0.8% in the 2nd quarter. Toth Financial Advisory Corp now owns 24,989 shares of the medical instruments supplier’s stock valued at $5,986,000 after purchasing an additional 203 shares during the period. Northwestern Mutual Wealth Management Co. lifted its stake in shares of Becton Dickinson and by 0.4% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 50,849 shares of the medical instruments supplier’s stock valued at $12,181,000 after purchasing an additional 204 shares during the period. Finally, Spearhead Capital Advisors LLC lifted its stake in shares of Becton Dickinson and by 1.4% in the 3rd quarter. Spearhead Capital Advisors LLC now owns 15,525 shares of the medical instruments supplier’s stock valued at $3,887,000 after purchasing an additional 218 shares during the period. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.

Further Reading: How Do You Calculate Return on Equity (ROE)?

The Fly

Analyst Recommendations for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply